000028:SSEChina National Accord Medicines Corporation Ltd. Analysis

China National Accord Medicines (000028) is trading near its 20‑day SMA of 25.86, with the 20‑day SMA sitting just above the 50‑day (25.54) and 200‑day (25.43) averages, suggesting a short‑term bullish bias. However, the MACD histogram is negative and the signal line has turned bearish, while RSI sits at a neutral 53, indicating limited momentum upside. The stock’s price is well below the DCF‑derived fair value of roughly 60 CNY, and its price‑to‑book ratio of 0.78 is attractive compared with peers. Valuation metrics such as a PE of 27 are in line with the industry average, but the low PB and a dividend yield of 1.42% with a 38% payout ratio point to a defensive, income‑oriented profile. Recent news of a Citi downgrade to “sell” adds a negative sentiment overlay, though the company’s low beta (≈0.09) and modest 30‑day volatility (~17.6%) keep systematic risk limited. Support at 25.12 and resistance at 26.77 frame a narrow trading range, and stable volume suggests adequate liquidity. Overall, the fundamentals show modest revenue contraction (‑1.9%) and thin margins, but strong cash generation and manageable debt (DE ratio ~25%) support dividend sustainability. The market’s “Extreme Greed” sentiment (FGI 75.9) may be overstating short‑term optimism, while the long‑term valuation gap remains sizable. Investors should weigh the near‑term bearish technical signal and downgrade against the deep value upside and steady dividend profile.
In sum, the stock appears undervalued on a balance‑sheet basis and offers a modest yield, yet momentum and sentiment pressures make a cautious short‑term stance prudent, while the long‑term case remains attractive if valuation re‑rates.